Encinitas, Calif. — Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, announced financial results for the fourth quarter and full year ended December 31, 2022, and highlighted recent pipeline...
finance News
SAN FRANCISCO – Today, VeriSIM Life (VeriSIM) announces the launch of its pharmaceutical subsidiary, PulmoSIM Therapeutics (PulmoSIM) with the mission to address the unmet needs in the treatment of rare respiratory diseases, with an immediate emphasis on pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF). PulmoSIM is developing breakthrough...
BOSTON & CAMBRIDGE, Mass. – Vertex Pharmaceuticals Incorporated (Nasdaq:VRTX) and Obsidian Therapeutics announced today that the two companies have entered into a strategic research collaboration and licensing agreement focused on the discovery of novel therapies that regulate gene editing for the treatment of serious diseases. The collaboration leverages Obsidian’s cytoDRiVE®...
LEIDEN, Netherlands — Vico Therapeutics B.V., a clinical-stage genetic medicines company developing therapies for severe neurological diseases, today announced a $60 million (€54 million) Series B financing. The financing was led by new investor Ackermans & van Haaren (AvH) with existing co-leads Droia Ventures, EQT Life Sciences and Kurma Partners...
SAN DIEGO — Viking Therapeutics, Inc. (“Viking”) (Nasdaq: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, announced the closing of its previously announced underwritten public offering of 19,828,300 shares of its common stock at a public offering price of $14.50 per...
SOUTH SAN FRANCISCO, Calif. — Vistagen, a late clinical-stage biopharmaceutical company aiming to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders, today announced that the European Patent Office (EPO) issued a Notice of Intention to Grant a patent related to the...
CAMBRIDGE, Mass. – Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the formation of a collaboration with Janssen Biotech, Inc. (“Janssen”), one of the Janssen Pharmaceutical Companies of Johnson...
Venture capital and angel investors are the lifeline of biotech companies. But what happens when obtaining an orphan drug designation no longer causes your stock price to double or triple in a matter of day, or allow you to do an IPO? Are VCs still interested? CheckOrphan rolled up its...
Chronic kidney disease (CKD) should be among the top health concerns of diabetes patients. Yet, while around 1 in 3 adults with diabetes has CKD, a Bayer survey of healthcare professionals shows that people are often unprepared for their diagnosis and that communication needs to improve. Bayer, which won approval...
ST. LOUIS & SAN DIEGO – Wugen, Inc., a clinical stage biotechnology company developing a pipeline of off-the-shelf cell therapies, today announced the completion of an oversubscribed $172 million Series B financing led by Abingworth and Tybourne Capital Management, and joined by new investors Fidelity Management & Research Company, Intermediate...